Predicting risk and treatment benefit in atherosclerosis: The role of C-reactive protein

International Journal of Cardiology

Volumn 98, Issue 2, 2005, Pages 199-206

  Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Atherosclerosis; C reactive protein; Statins

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; COLONY STIMULATING FACTOR 1; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN; PROTEIN DERIVATIVE; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL ADHESION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; DRUG MEGADOSE; DRUG TARGETING; HUMAN; INFLAMMATION; INTIMA; PATHOGENESIS; PLAQUE FORMING CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE;

EID: 15944410610     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.05.019     Document Type: Review

References (89)

1. P. Libby Molecular bases of acute coronary syndromes Circulation 91 1995 2844 2850
2. D.H. Blankenhorn, S.P. Azen, D.M. Kramsch and the MARS Research Group Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS) Ann. Intern. Med. 119 1993 969 976
3. MAAS Investigators Effect of simvastatin on coronary atheroma: the Mutlicentre Anti-Atheroma Study (MAAS) Lancet 344 1994 633 638
4. D. Waters, L. Higginson, and P. Gladstone Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial Circulation 89 1994 959 968
5. B. Pitt, G.B. Mancini, S.G. Ellis, H.S. Rosman, J.S. Park, and M.E. McGovern Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation J. Am. Coll. Cardiol. 26 1995 1133 1139
6. S. Nissen Coronary angiography and intravascular ultrasound Am. J. Cardiol. 87 2001 15A 20A [Suppl.]
7. W.C. Little, M. Constantinescu, and R.J. Applegate Can coronary angiography predict the site of a subsequent myocardial infarction on patients with mild to moderate coronary artery disease? Circulation 78 1988 1157 1166
8. R. Ross Atherosclerosis-an inflammatory disease N. Engl. J. Med. 340 1999 115 126
9. G.J. Blake, and P.M. Ridker Inflammatory bio-markers and cardiovascular risk prediction J. Intern. Med. 252 2002 283 294
10. J. Plutzky Inflammatory pathways in atherosclerosis and acute coronary syndromes Am. J. Cardiol. 88 2001 10K 15K [Suppl.]
11. E. Braunwald Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities N. Engl. J. Med. 337 1997 1360 1369
12. P. Libby Changing concepts of atherogenesis J. Intern. Med. 247 2000 349 358
13. J.K. Liao Beyond lipid lowering: the role of statins in vascular protection Int. J. Cardiol. 86 2002 5 18
14. P.S. Frenette, R.C. Johnson, R.O. Hynes, and D.D. Wagner Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin Proc. Natl. Acad. Sci. U. S. A. 92 1995 7450 7454
15. H. Li, M.I. Cybulsky, M.A. Gimbrone Jr., and P. Libby Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma Am. J. Pathol. 143 1993 1551 1559
16. L. Gu, Y. Okada, and S.K. Clinton Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice Mol. Cell 2 1998 275 281
17. J.H. Qiao, J. Tripathi, and N.K. Mishra Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice Am. J. Pathol. 150 1997 1687 1699
18. S. Bhakdi, M. Torzewski, M. Klouche, and M. Hemmes Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation Arterioscler. Thromb. Vasc. Biol. 19 1999 2348 2354
19. S.J. Warner, and P. Libby Human vascular smooth muscle cells. Target for and source of tumor necrosis factor J. Immunol. 142 1989 100 109
20. P. Barath, M.C. Fishbein, J. Cao, J. Berenson, R.H. Helfant, and J.S. Forrester Detection and localization of tumor necrosis factor in human atheroma Am. J. Cardiol. 65 1990 297 302
21. P.C. Heinrich, J.V. Castell, and T. Andus Interleukin-6 and the acute phase response Biochem. J. 265 1990 621 636
22. Y. Seino, U. Ikeda, and M. Ikeda Interleukin 6 gene transcripts are expressed inhuman atherosclerotic lesions Cytokine 6 1994 87 91
23. H.G. Rus, R. Vlaicu, and F. Niculescu Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall Atherosclerosis 127 1996 263 271
24. P.M. Ridker, N. Rifai, M.J. Stampfer, and C.H. Hennekens Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men Circulation 101 2000 1767 1772
25. P.M. Ridker, N. Rifai, M. Pfeffer, F. Sacks, S. Lepage, E. Braunwald for the Cholesterol and Recurrent Events (CARE) Investigators Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction Circulation 101 2000 2149 2153
26. S.J. Hwang, C.M. Ballantyne, and A.R. Sharrett Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study Circulation 96 1997 4219 4225
27. P.M. Ridker, C.H. Hennekens, B. Roitman-Johnson, M.J. Stampfer, and J. Allen Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men Lancet 351 1998 88 92
28. P.M. Ridker, J.E. Buring, and N. Rifai Soluble P-selectin and the risk of future cardiovascular events Circulation 103 2001 491 495
29. J. Danesh, P. Whinchup, and M. Walker Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses BMJ 321 2000 199 204
30. P.M. Ridker, C.H. Hennekens, J.E. Buring, and N. Rifai C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N. Engl. J. Med. 342 2000 836 843
31. M.B. Pepys, and G.M. Hirschfield C-reactive protein: a critical update J. Clin. Invest.J. Clin. Invest. 111 2003 1805 1812
32. H.K. Meier-Ewert, P.M. Ridker, N. Rifai, M. Price, D.F. Dinges, and J.M. Mullington Absence of diurnal variation of C-reactive protein concentrations in healthy subjects Clin. Chem. 47 2001 426 430
33. M. Fröhlich, M. Sund, and S. Russ Seasonal variations of rheological and hemostatic parameters, and acute phase reactants in young, healthy subjects Arterioscler. Thromb. Vasc. Biol. 17 1997 2692 2697
34. M. Fröhlich, M. Sund, B. Thorand, W.L. Hutchinson, M.B. Pepys, and W. Koenig Lack of seasonal variation in C-reactive protein Clin. Chem. 48 2002 575 577
35. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks, E. Braunwald for the Cholesterol and Recurrent Events (CARE) Investigators Long-term effects of pravastatin on plasma concentration of C-reactive protein Circulation 100 1999 230 235
36. N. Rifai, R.P. Tracy, and P.M. Ridker Clinical efficacy of an automated high-sensitivity C-reactive protein assay Clin. Chem. 45 1999 2136 2141
37. N. Khuseyinova, A. Imhof, G. Trischler, D. Rothenbacher, W.L. Hutchinson, and M.B. Pepys Determination of C-reactive protein: comparison of three high-sensitivity immunoassays Clin. Chem. 49 2003 1691 1695
38. W. Koenig, M. Sund, M. Fröhlich, H. Löwel, W.L. Hutchinson, and M.B. Pepys Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time. Results from the MONICA-Augsburg studies 1984 and 1987 Am. J. Epidemiol. 158 2003 357 364
39. I.S. Ockene, C.E. Matthews, N. Rifai, P.M. Ridker, G. Reed, and E. Stanek Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults Clin. Chem. 47 2001 444 450
40. T.A. Pearson, G.A. Mensah, and R.W. Alexander Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
41. J.S. Yudkin, C.D. Stehouwer, J.J. Emeis, and S.W. Coppack C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19 1999 972 978
42. G.J. Blake, N. Rifai, J.E. Buring, and P.M. Ridker Blood pressure, C-reactive protein, and risk of future cardiovascular events Circulation 108 2003 2993 2999
43. H.D. Sesso, J.E. Buring, and N. Rifai C-reactive protein and the risk of developing hypertension JAMA 290 2003 2945 2951
44. A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring, and P.M. Ridker C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 286 2001 327 334
45. P.M. Ridker, J.E. Buring, N.R. Cook, and N. Rifai C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women Circulation 107 2003 391 397
46. M.P. Stern Diabetes and cardiovascular disease. The "common soil" hypothesis Diabetes 44 1995 369 374
47. A.D. Pradhan, and P.M. Ridker Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur. Heart J. 23 2002 831 834
48. G.J. Blake, and P.M. Ridker Novel clinical markers of vascular wall inflammation Circ. Res. 89 2001 763 771
49. S. Manzi, E.N. Meilahn, and J.E. Rairie Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study Am. J. Epidemiol. 145 1997 408 415
50. D.H. Solomon, E.W. Karlson, and E.B. Rimm Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis Circulation 107 2003 1202 1307
51. P.H. Dessein, A.E. Stanwix, and B.I. Joffe Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis Arthritis Res. 4 2002 R5
52. M. Roivainen, M. Viik-Kajander, and T. Palosuo Infections, inflammation, and the risk of coronary heart disease Circulation 101 2000 252 257
53. V. Pasceri, J.T. Willerson, and E.T.H. Yeh Direct proinflammatory effect of C-reactive protein on human endothelial cells Circulation 102 2000 2165 2168
54. V. Pasceri, J. Chang, J.T. Willerson, and E.T.H. Yeh Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs Circulation 103 2001 2531 2534
55. M. Torzewski, C. Rist, and R.F. Mortensen C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis Arterioscler. Thromb. Vasc. Biol. 20 2000 2094 2099
56. T.P. Zwaka, V. Hombach, and J. Torzewski C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis Circulation 103 2001 1194 1197
57. C.H. Wang, S.H. Li, and R.D. Weisel C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle Circulation 107 2003 1783 1790
58. K. Yasojima, C. Schwab, E.G. McGeer, and P.L. McGeer Generation of C-reactive protein and complement components in atherosclerotic plaques Am. J. Pathol. 158 2001 1039 1051
59. B.C. Berk, W.S. Weintraub, and R.W. Alexander Elevation of C-reactive protein in "active" coronary artery disease Am. J. Cardiol. 65 1990 168 172
60. G. Liuzzo, L.M. Biasucci, and J.R. Gallimore The prognostic value of C-reactive protein in severe unstable angina N. Engl. J. Med. 331 1994 417 424
61. D.A. Morrow, N. Rifai, and E.M. Antman C-reactive protein predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in myocardial infartion J. Am. Coll. Cardiol. 31 1998 1460 1465
62. C. Heeschen, C.W. Hamm, J. Bruemmer, and M.L. Simoons Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial J. Am. Coll. Cardiol. 35 2000 1535 1542
63. B. Lindahl, H. Toss, A. Siegbahn, P. Venge, L. Wallentin for the FRISC study group Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease N. Engl. J. Med. 343 2000 1139 1147
64. P.M. Ridker, N. Rifai, M.A. Pfeffer for the Cholesterol and Recurrent Events (CARE) Investigators Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels Circulation 98 1998 839 844
65. L. Retterstol, L. Eikvar, M. Bohn, A. Bakken, J. Erikssen, and K. Berg C-reactive protein predicts death in patients with previous premature myocardial infarction-a 10 year follow-up study Atherosclerosis 160 2002 433 440
66. T.S. Harb, W. Zareba, A.J. Moss THROMBO Investigators Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction Am. J. Cardiol. 89 2002 216 221
67. P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, and N.R. Cook Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N. Engl. J. Med. 347 2002 1557 1565
68. R.P. Tracy, R.N. Lemaitre, and B.M. Psaty Relationship of C-reactive protein to risk of cardiovascular disease in the elderly Arterioscler. Thromb. Vasc. Biol. 17 1997 1121 1127
69. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N. Engl. J. Med. 336 1997 973 979
70. C.M. Albert, J. Ma, and N. Rifai Prospective study of C1-1 reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death Circulation 105 2002 2595 2599
71. N.S. Rost, P.A. Wolf, and C.S. Kase Plasma concentration of C-reactive protein and the risk of ischemic stroke and transient ischemic attack Stroke 32 2001 2575 2579
72. G.D. Lowe, J.W. Yarnell, A. Rumley, D. Bainton, and P.M. Sweetnam C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler. Thromb. Vasc. Biol. 21 2001 603 610
73. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease Circulation 97 1998 425 428
74. W. Koenig, M. Sund, and M. Fröhlich C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992 Circulation 99 1999 237 242
75. R.H. Knopp Drug treatment of lipid disorders N. Engl. J. Med. 341 1999 498 511
76. A.G. Olsson, F. McTaggart, and A. Raza Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor Cardiovasc. Drug Rev. 20 2002 303 328
77. M. Crisby, G. Nordin-Fredriksson, P.H. Shah, J. Yano, J. Zhu, and J. Nilsson Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization Circulation 103 2001 926 933
78. S. Bellosta, D. Via, and M. Canavesi HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages Arterioscler. Thromb. Vasc. Biol. 18 1998 1671 1678
79. C. Bustos, M.A. Hernandez-Presa, and M. Ortego HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis J. Am. Coll. Cardiol. 32 1998 2057 2064
80. M. Aikawa, E. Rabkin, and S. Sugiyama An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro Circulation 103 2001 276 283
81. S. Niwa, T. Totsuka, and S. Hayashi Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line Int. J. Immunopharmacol. 18 1996 669 675
82. T.J. Stalker, A.M. Lefer, and R. Scalia A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid Br. J. Pharmacol. 133 2001 406 412
83. M.A. Albert, E. Danileson, N. Rifai, P.M. Ridker PRINCE Investigators Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
84. I. Jialal, D. Stein, D. Balis, S.M. Grundy, B. Adams-Huet, and S. Devaraj Effect of hydroxylmethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels Circulation 103 2001 1933 1935
85. P.M. Ridker, N. Rifai, and S.P. Lowenthal Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholeserolemia Circulation 103 2001 1191 1193
86. B.J. Ansell, K.E. Watson, R.E. Weiss, and G.C. Fonarow hsCRP and HDL Effects Statin Trial (CHEST): rapid of effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation Heart Dis. 5 2003 2 7
87. E.A. Stein, K. Strutt, H. Southworth, P.J. Diggle, E. Millor on behalf of the HeFH Study Group Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia Am. J. Cardiol. 92 2003 1287 1293
88. P.M. Ridker, N. Rifai, M. Clearfield for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N. Engl. J. Med. 344 2001 1959 1965
89. P.M. Ridker Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial Circulation 108 2003 2292 2297